October 25, 2021
Summary of Diet Intervention Studies in Multiple Sclerosis from the National MS Society Nutrition Wellness Subgroup
Background: Increasing evidence suggests that lifestyle factors such as dietary patterns and exercise impact the risk and course of...
October 25, 2021
Prefrontal Metabolism Is Associated with Processing Speed in Multiple Sclerosis: A Calibrated fMRI Study
Background: Cognitive processing speed deficits are common in multiple sclerosis (MS). Despite this, the exact neural mechanism underlying...
Poster-Disease-modifying Therapy
October 25, 2021
Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study
Background: Siponimod showed beneficial effects on magnetic resonance imaging (MRI) lesion activity, total brain and gray matter (GM)...
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years
Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...
Poster-Disease-modifying Therapy
October 25, 2021
Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis
Background: Ozanimod is approved in the US for the treatment of adults with relapsing multiple sclerosis (RMS) and in the EU and Canada for...
Poster-Disease-modifying Therapy
October 25, 2021
Psoriasis in Multiple Sclerosis Patients Treated with Disease Modifying Therapies
Background: Psoriasis may be more common in people living with multiple sclerosis (PwMS) than in the general population. Some pathways...
Poster-Disease-modifying Therapy
October 25, 2021
Alopecia in Multiple Scleoris Patients Treated with Disease Modifying Therapies
Background: There is limited literature about the frequency of alopecia in people with multiple sclerosis (MS) treated with disease...
Poster-Disease-modifying Therapy
October 25, 2021
Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a
Background: Although socioeconomic disparities that lead to differences in multiple sclerosis (MS) outcomes have been identified, specific...
Poster-Disease-modifying Therapy
October 25, 2021
Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS
Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...
Poster-Disease-modifying Therapy
October 25, 2021
Effect of Age on the Change of Lymphocytes and Immunoglobulins during Treatment with Ocrelizumab or Rituximab for Multiple Sclerosis and Related Disorders
Background: Depletion of B lymphocytes is a known therapeutic strategy for multiple sclerosis (MS) and related disorders. Ocrelizumab (OCR)...